Bextra Settlement Coming Soon: Industry Should Brace for Impact
This article was originally published in RPM Report
Executive Summary
Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety
You may also be interested in...
Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks
Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.
Allergan's Botox Off-Label Promotion Suit Raises Questions, But Why Would Wall Street Care?
Allergan's lawsuit against FDA over post-marketing safety restrictions for Botox is yet another new wrinkle that may help define the significance of the new "Safety First" regulatory era. But there is more to this case than meets the eye.
The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement
States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.